Paradigm Biopharmaceuticals shares lower despite US update

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price was down 5.1% today despite announcing it has treated its first patient with Zilosul in the US.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price was down as much as 5.1% today despite the announcement that it has treated its first patient with Zilosul in the United States.

A former NFL player is the first patient to receive injections of Zilosul in the US under the Federal Drug Administration's Expanded Access Program. 

At the time of writing, Paradigm shares are trading 3.16% lower for the day at $3.99 per share.

Use of Zilosul

Paradigm is seeking to commercialise the use of Zilosul to treat knee osteoarthritis. Zilosul (iPPS) is not registered in Australia but was previously registered in Europe as an antithrombotic agent.

Paradigm has developed an injectable form of iPPS (Zilosul) which it believes can be used to treat osteoarthritis.

Use of Zilosul under Expanded Access Program

Under the Expanded Access Program, 10 ex-NFL players will receive two Zilosul injections per week over a six week period. This treatment is in line with the proposed treatment protocol for Paradigm's proposed Phase 3 pivotal study.

Each patient is first screened to measure their baseline pain scores and given MRI scans to determine the presence of Bone Marrow Edema Lesions within the knee joint. Follow up scans and pain measurements will be taken 6 weeks after the completion of treatment. 

The remaining nine patients to be treated under the Expanded Access Program are staggered to commence over the next 4 weeks, with the last patients expected to receive their final dose in mid-May. Paradigm expects to report data on patient outcomes early in the third quarter of 2020. 

What is the Expanded Access Program? 

The Expanded Access Program provides a pathway for patients to gain access to investigational drugs intended to treat serious diseases or conditions for which there are no comparable or satisfactory options outside of clinical trials.

The FDA recognises that osteoarthritis can be a serious disease with an unmet need for therapies that can potentially change the course of the disease to prevent long-term disability. 

In males under the age of 60, osteoarthritis is three times more common in retired NFL players than in the general population, possibly due to the high incidence of injury in football.

Mitch Marrow, a former NFL player who was treated with iPPS in Australia under a special access program, said, "the treatment was so life changing in treating my years of pain and lack of mobility that I am thrilled more former NFL players will have access to this incredible drug in the US under the expanded access program."

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »